TY - JOUR
A2 - Akanmori, Bartholomew
AU - Perambakam, Supriya
AU - Xie, Hui
AU - Edassery, Seby
AU - Peace, David J.
PY - 2010
DA - 2011/01/05
TI - Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
SP - 473453
VL - 2010
AB - Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P=.02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.
SN - 2314-8861
UR - https://doi.org/10.1155/2010/473453
DO - 10.1155/2010/473453
JF - Clinical and Developmental Immunology
PB - Hindawi Publishing Corporation
KW -
ER -